Noah Berkowitz - 26 Feb 2026 Form 4 Insider Report for ARVINAS, INC. (ARVN)

Reporting relationship: Chief Medical Officer
Issuer ticker: ARVN
Reported as of: 26 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2026, 20:59:46 UTC
Prior SEC filing: 18 Feb 2026
Next SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz

Key filing fact

Noah Berkowitz filed Form 4 for ARVINAS, INC. (ARVN) on 02 Mar 2026.

Key facts

This page summarizes Noah Berkowitz's Form 4 filing for ARVINAS, INC. (ARVN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2026, 20:59.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001369900 Primary reporting owner

Berkowitz Noah

Relationship: Chief Medical Officer
Address: C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN
Signature: /s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz
Signature date: 02 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARVN transaction

Common Stock

Award

Transaction value: $0
Shares: +45,000
Change %: +27%
Price: $0.000000
Shares after: 208,938
Date: 26 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARVN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +67,000
Change %
Price: $0.000000
Shares after: 67,000
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 67,000
Exercise price: $13.38
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Footnote F2

The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date.